PRLD — Prelude Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$5.49
-$0.11 (-1.96%)
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ. It is led by Krishna Vaddi D.V.M., Ph.D., based in 175 Innovation Boulevard, Wilmington, DE, United States, 19805, with about 79 employees. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Latest reported PRLD revenue for 2025-09-30 was $6.5M. Net income was -$83.0M. PRLD currently screens at market cap $346.5M.
Use this PRLD page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PRLD quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PRLD SEC filings page. Lician reads the product cache first so this HTML stays unique to Prelude Therapeutics Inc even when a live quote feed is slow.
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
PRLD Key Statistics
Market Cap
$346.46M
Volume
274,018
Previous Close
$6.47
Day Range
$6.31 – $6.70
P/B Ratio
5.74
EPS
-$1.68
Revenue
$7.00M
Net Income
-$127.17M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-1816.8%
Employees
79
PRLD Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $7.00M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$127.17M | -$121.83M | -$115.44M | -$111.69M |
| EPS (Diluted) | -$1.68 | -$2.02 | -$2.44 | -$2.43 |
Total Assets
$175.51M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$12.47M
Operating Cash Flow
-$102.89M
Free Cash Flow
$0.00
Prelude Therapeutics Inc Company Information
- Founder, CEO & Director
- Krishna Vaddi D.V.M., Ph.D.
- Headquarters
- 175 Innovation Boulevard, Wilmington, DE, United States, 19805
- Website
- preludetx.com
- Phone
- 302 467 1280
- IPO / Founded
- 2020-09-25
- Sector
- Healthcare
- Industry
- Biotechnology